Literature DB >> 11553539

CD85/LIR-1/ILT2 and CD152 (cytotoxic T lymphocyte antigen 4) inhibitory molecules down-regulate the cytolytic activity of human CD4+ T-cell clones specific for Mycobacterium tuberculosis.

A Merlo1, D Saverino, C Tenca, C E Grossi, S Bruno, E Ciccone.   

Abstract

Antigen-specific cytolytic CD4+ T lymphocytes control Mycobacterium tuberculosis infection by secreting cytokines and by killing macrophages that have phagocytosed the pathogen. However, lysis of the latter cells promotes microbial dissemination, and other macrophages engulf the released bacteria. Subsequently, CD4+ T-cell-mediated killing of macrophages goes on, and this persistent process may hamper control of infection, unless regulatory mechanisms maintain a subtle balance between lysis of macrophages by cytolytic CD4+ cells and activation of cytolytic CD4+ cells by infected macrophages. We asked whether inhibitory molecules expressed by CD4+ cytolytic T lymphocytes could play a role in such a balance. To this end, human CD4+ T-cell clones specific for M. tuberculosis were produced that displayed an autologous major histocompatibility complex class II-restricted lytic ability against purified protein derivative (PPD)-pulsed antigen-presenting cells. All T-cell clones expressed CD152 (cytotoxic T-lymphocyte antigen 4 [CTLA-4]) and CD85/leukocyte immunoglobulin-like receptor 1 (LIR-1)/immunoglobulin-like transcript 2 (ILT2) inhibitory receptors, but not CD94 and the killer inhibitory receptor (or killer immunoglobulin-like receptor [KIR]) p58.2. CD3-mediated activation of the clones was inhibited in a redirected killing assay in which CD152 and CD85/LIR-1/ILT2 were cross-linked. Specific antigen-mediated proliferation of the clones was also sharply reduced when CD152 and CD85/LIR-1/ILT2 were cross-linked by specific monoclonal antibody (MAb) followed by goat anti-mouse antiserum. In contrast, blockade of the receptors by specific MAb only increased their proliferation. Production of interleukin 2 (IL-2) and gamma interferon (IFN-gamma) by the T-cell clones was also strongly reduced when CD152 and CD85/LIR-1/ILT2 were cross-linked. The lytic activity of the T-cell clones against PPD-pulsed autologous monocytes or Epstein-Barr virus-activated B cells was increased by blockade and decreased by cross-linking of the receptors. These results indicate that CD152 and CD85/LIR-1/ILT2 play a role in the regulation of the antigen-specific activity of CD4+ cytolytic T lymphocytes against PPD-presenting cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11553539      PMCID: PMC98730          DOI: 10.1128/IAI.69.10.6022-6029.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  34 in total

1.  The inhibitory receptor LIR-1 uses a common binding interaction to recognize class I MHC molecules and the viral homolog UL18.

Authors:  T L Chapman; A P Heikeman; P J Bjorkman
Journal:  Immunity       Date:  1999-11       Impact factor: 31.745

Review 2.  The expanding world of co-stimulation: the two-signal model revisited.

Authors:  C A Chambers
Journal:  Trends Immunol       Date:  2001-04       Impact factor: 16.687

3.  Cytokine secretion by CD4 T lymphocytes acquired in response to Mycobacterium tuberculosis infection.

Authors:  I M Orme; A D Roberts; J P Griffin; J S Abrams
Journal:  J Immunol       Date:  1993-07-01       Impact factor: 5.422

4.  Naive human T cells develop into Th1 effectors after stimulation with Mycobacterium tuberculosis-infected macrophages or recombinant Ag85 proteins.

Authors:  D M Russo; N Kozlova; D L Lakey; D Kernodle
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

5.  Granulysin, a T cell product, kills bacteria by altering membrane permeability.

Authors:  W A Ernst; S Thoma-Uszynski; R Teitelbaum; C Ko; D A Hanson; C Clayberger; A M Krensky; M Leippe; B R Bloom; T Ganz; R L Modlin
Journal:  J Immunol       Date:  2000-12-15       Impact factor: 5.422

6.  T-cell release of granulysin contributes to host defense in leprosy.

Authors:  M T Ochoa; S Stenger; P A Sieling; S Thoma-Uszynski; S Sabet; S Cho; A M Krensky; M Rollinghoff; E Nunes Sarno; A E Burdick; T H Rea; R L Modlin
Journal:  Nat Med       Date:  2001-02       Impact factor: 53.440

7.  The CD85/LIR-1/ILT2 inhibitory receptor is expressed by all human T lymphocytes and down-regulates their functions.

Authors:  D Saverino; M Fabbi; F Ghiotto; A Merlo; S Bruno; D Zarcone; C Tenca; M Tiso; G Santoro; G Anastasi; D Cosman; C E Grossi; E Ciccone
Journal:  J Immunol       Date:  2000-10-01       Impact factor: 5.422

8.  Mycobacteria induce CD4+ T cells that are cytotoxic and display Th1-like cytokine secretion profile: heterogeneity in cytotoxic activity and cytokine secretion levels.

Authors:  T Mutis; Y E Cornelisse; T H Ottenhoff
Journal:  Eur J Immunol       Date:  1993-09       Impact factor: 5.532

9.  Evidence for inhibition of fusion of lysosomal and prelysosomal compartments with phagosomes in macrophages infected with pathogenic Mycobacterium avium.

Authors:  C Frehel; C de Chastellier; T Lang; N Rastogi
Journal:  Infect Immun       Date:  1986-04       Impact factor: 3.441

10.  CTLA-4 blockade enhances the immune response induced by mycobacterial infection but does not lead to increased protection.

Authors:  J Kirman; K McCoy; S Hook; M Prout; B Delahunt; I Orme; A Frank; G Le Gros
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

View more
  17 in total

1.  [Clinical presentation of tuberculosis in routine practice].

Authors:  R Dinser; M Frerix; U Müller-Ladner
Journal:  Z Rheumatol       Date:  2012-10       Impact factor: 1.372

Review 2.  Antigen presentation and the ubiquitin-proteasome system in host-pathogen interactions.

Authors:  Joana Loureiro; Hidde L Ploegh
Journal:  Adv Immunol       Date:  2006       Impact factor: 3.543

3.  Friends and foes of tuberculosis: modulation of protective immunity.

Authors:  S Brighenti; S A Joosten
Journal:  J Intern Med       Date:  2018-05-27       Impact factor: 8.989

4.  Inhibitory receptors CD85j, LAIR-1, and CD152 down-regulate immunoglobulin and cytokine production by human B lymphocytes.

Authors:  Andrea Merlo; Claudya Tenca; Franco Fais; Lorenzo Battini; Ermanno Ciccone; Carlo E Grossi; Daniele Saverino
Journal:  Clin Diagn Lab Immunol       Date:  2005-06

5.  Human papillomavirus immunization is associated with increased expression of different innate immune regulatory receptors.

Authors:  V Colmenares; D E Noyola; A Monsiváis-Urenda; M Salgado-Bustamante; L Estrada-Capetillo; R González-Amaro; L Baranda
Journal:  Clin Vaccine Immunol       Date:  2012-05-09

6.  Granulysin-expressing CD4+ T cells as candidate immune marker for tuberculosis during childhood and adolescence.

Authors:  Henrik Mueller; Kellen C Faé; Klaus Magdorf; Christian A Ganoza; Ulrich Wahn; Ute Guhlich; Cornelia Feiterna-Sperling; Stefan H E Kaufmann
Journal:  PLoS One       Date:  2011-12-27       Impact factor: 3.240

7.  Downregulation of immunoglobulin-like transcript-4 (ILT4) in patients with psoriatic arthritis.

Authors:  Alberto Bergamini; Maria Sole Chimenti; Eleonora Baffari; Maria Domenica Guarino; Gianfranco Gigliucci; Carlo Perricone; Roberto Perricone
Journal:  PLoS One       Date:  2014-03-27       Impact factor: 3.240

8.  Modulation of the inhibitory receptor leukocyte Ig-like receptor 1 on human natural killer cells.

Authors:  Nicholas L Li; Chelsea L Davidson; Atul Humar; Deborah N Burshtyn
Journal:  Front Immunol       Date:  2011-09-20       Impact factor: 7.561

9.  Inhibitory receptors are expressed by Trypanosoma cruzi-specific effector T cells and in hearts of subjects with chronic Chagas disease.

Authors:  Rafael J Argüello; María C Albareda; María G Alvarez; Graciela Bertocchi; Alejandro H Armenti; Carlos Vigliano; Patricia C Meckert; Rick L Tarleton; Susana A Laucella
Journal:  PLoS One       Date:  2012-05-04       Impact factor: 3.240

Review 10.  Inhibitory leukocyte immunoglobulin-like receptors: Immune checkpoint proteins and tumor sustaining factors.

Authors:  Xunlei Kang; Jaehyup Kim; Mi Deng; Samuel John; Heyu Chen; Guojin Wu; Hiep Phan; Cheng Cheng Zhang
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.